tirzepatide launch date FDA approves tirzepatide, Eli Lilly's new type 2 diabetes drug, and the company shares an estimated price Successfully Launch! >>> The Metabolic

The STEP 1 extension data showed that patients who stopped semaglutide regained roughly two-thirds of their lost weight within a year

Very rare in the trials and not consistently linked to retatrutide specifically, but a known concern across the GLP-1 family

100% motor capacity has been reached by three patients within the first 3 months of this study (98)

Modifying your eating patterns and food choices represents one of the most effective strategies for minimizing stomach pain associated with Zepbound

As a result, the urine looks darker and smells stronger, often like ammonia

Retatrutide is being studied as a triple agonist, targeting GLP-1, GIP, and glucagon receptors, potentially offering even more comprehensive metabolic benefits and weight loss than tirzepatide, which only targets GLP-1 and GIP